ArticleOncogene2026
SETDB1 cooperates with the CRL4B complex to promote colorectal cancer tumorigenesis by disrupting circadian rhythm.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The circadian rhythm is an intrinsic, self-regulatory physiological system in organisms that is hierarchically governed by core clock genes. Dysregulation of this rhythm is closely associated with tumor progression. However, the specific molecular mechanisms underlying circadian rhythm disruption-mediated colorectal cancer (CRC) remain largely elusive. The histone methyltransferase SET domain bifurcated 1 (SETDB1) exerts oncogenic functions in multiple solid tumors, prompting this study to investigate the molecular mechanisms through which SETDB1 regulates CRC progression. Our results demonstrate that SETDB1 acts as an oncogene in CRC by interacting with the Cullin 4B-RING E3 ligase (CRL4B) complex to enhance cancer cell proliferation, invasion, and stemness maintenance. Specifically, SETDB1 and the CRL4B complex assemble into a transcriptional repressor complex that binds to the promoters of core clock genes, such as PER3 and CRY1, to repress their transcription, thereby disrupting cellular circadian rhythms and ultimately accelerating CRC cell proliferation and metastasis. Collectively, our findings elucidate the pivotal role of the SETDB1/CRL4B complex in CRC pathogenesis and provide a potential therapeutic strategy targeting SETDB1 for patients with CRC with high CUL4B expression.
Identifiers
42778664What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.